Latest Edition,Formula. C187H291N45O59

The ozempic semaglutide peptide structure is a fascinating area of scientific inquiry, revealing the intricate design of a molecule that has revolutionized the management of type 2 diabetes and weight management. At its core, semaglutide is a peptide, a molecule composed of a specific linear sequence of 31 amino acids joined together by peptide linkages. This intricate arrangement dictates its function and efficacy.

Understanding the structure of semaglutide is crucial to appreciating its mechanism of action. It is fundamentally a long-acting glucagon-like peptide-1 (GLP-1) analogue. Glucagon-like peptide-1 (GLP-1) is a naturally occurring hormone produced by the digestive system, playing a vital role in regulating glucose metabolism. Semaglutide shares a remarkable 94% sequence homology with human glucagon-like peptide-1 (GLP-1), meaning it closely mimics the native peptide’s actions while offering enhanced stability and duration of effect.

The precise ozempic semaglutide peptide structure involves specific modifications to the native GLP-1 sequence. It is a modified analogue of glucagon-like peptide 1-(7-37). Two key amino acid substitutions distinguish it: at position 8, alanine has been replaced by $\alpha$-aminobutyric acid (Aib), and at position 34, alanine is replaced by arginine. These alterations are critical for its improved pharmacokinetic properties, including resistance to degradation by dipeptidyl peptidase-4 (DPP-4) and enhanced binding affinity to the GLP-1 receptor. Furthermore, semaglutide is derivatized at lysine 26 with a fatty acid, which contributes to its prolonged half-life, allowing for less frequent administration, such as the once-weekly injection regimen associated with Ozempic. The chemical formula for semaglutide is C187H291N45O59, with a molecular weight of approximately 4113.58 g/mol. This detailed chemical composition underscores its complex peptide nature.

The semaglutide peptide backbone has been a subject of extensive crystallographic study, providing detailed insights into its three-dimensional conformation. These studies reveal how the semaglutide peptide structure interacts with the GLP-1 receptor. For instance, specific amino acids within the semaglutide chain form hydrogen bonds with residues on the GLP-1 receptor's extracellular domain, facilitating receptor activation. The structure is often depicted as a long chain, but its folding and interactions are dynamic and essential for its biological activity.

For those seeking detailed structural information, resources like PubChem and the Protein Data Bank (PDB) offer comprehensive data. PubChem provides the Formula. C187H291N45O59 and exact mass, alongside other physicochemical properties and database links for semaglutide. The PDB offers crystallographic data, such as the crystal structure of the semaglutide peptide backbone in complex with the GLP-1 receptor, allowing researchers to visualize these molecular interactions.

In summary, the ozempic semaglutide peptide structure is a sophisticated peptide designed to mimic and enhance the action of the natural incretin hormone GLP-1. Its linear sequence of 31 amino acids, coupled with strategic modifications, allows it to act as a potent and selective GLP-1 receptor agonist, leading to improved glycemic control and other metabolic benefits. The exploration of its structure continues to be a vital area of research, contributing to our understanding of peptide therapeutics and their applications in treating complex diseases.